NDA 213953 · Marius
Kyzatrex
Testosterone Undecanoate · Oral
Last checked: Nov 20, 2026Latest source record: Jul 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Jul 27, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
82
23 Phase 3, 9 recruiting
FAERS reports
259
209 serious, 20 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 5, 2026.
KYZATREX® is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (folliclestimulating hormone (FSH), luteinizing hormone (LH)) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low serum testosterone concentrations but have gonadotropins in the normal or low range. KYZATREX® is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone ( 1 ). Limitations of Use: Safety and efficacy of KYZATREX® in males less than 18 years old have not been established ( 1 , 8.4 ). Safety and efficacy of KYZATREX® in men with “age-related hypogonadism” have not been established (1) . Limitations of Use Safety and efficacy of KYZATREX® in males less than 18 years old have not been established [see Use in Specific Populations (8.4) ] . Safety and efficacy of KYZATREX® in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established.
Mechanism: Endogenous androgens, including testosterone and dihydrotestosterone (DHT), are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of prostate, seminal vesicles, penis, and scrotum; the development of male hair distribution, such as facial, pubic, chest, and axillary hair; laryngeal enlargement; vocal cord thickening; alterations in body musculature; and fat distribution. Male hypogonadism, a clinical syndrome resulting from insufficient secretion of testosterone, has...
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
4 products under this application
- KYZATREX · TESTOSTERONE UNDECANOATE 200MG · CAPSULE, ORAL · Prescription
- KYZATREX · TESTOSTERONE UNDECANOATE 100MG · CAPSULE, ORAL · Discontinued
- KYZATREX · TESTOSTERONE UNDECANOATE 50MG · CAPSULE, ORAL · Prescription
- KYZATREX · TESTOSTERONE UNDECANOATE 150MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Testosterone Undecanoate" as an intervention, any sponsor and status, largest first.
- A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With HypogonadismPivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT04456296 · 673 participants · Start Jun 30, 2020 · Primary completion Jul 12, 2023
Drug: Aveed Injectable Product; Fortesta and 1 more · For: Hypogonadism; Hypogonadism, Male; Hypogonadotropic Hypogonadism
Sites: Birmingham, Alabama; Tucson, Arizona; North Little Rock, Arkansas · 35 sites in all
- Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal MenPivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT00467870 · 531 participants · Start Mar 2006 · Primary completion Jul 2009
Drug: Testosterone Undecanoate 750 mg; Testosterone Undecanoate 1000 mg · For: Hypogonadism; Primary Hypogonadism; Secondary Hypogonadism
Sites: Lexington, Massachusetts
- Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00403793 · 350 participants · Start Oct 2003 · Primary completion Dec 2006
Drug: etonogestrel with testosterone undecanoate; Placebo · For: Contraception
- Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal MenPivotal-lookingCompleted
Clarus Therapeutics, Inc.Industry
NCT01403116 · 325 participants · Start Jul 2011 · Primary completion Sep 2013
Drug: Oral testosterone undecanoate; topical testosterone gel · For: Male Hypogonadism
Sites: Birmingham, Alabama; Calera, Alabama; Huntsville, Alabama · 30 sites in all
- Effects of Andriol Testocaps in Symptomatic Late-Onset Hypogonadism (43203)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00434824 · 322 participants · Start Nov 2001 · Primary completion Jul 2004
Drug: Oral testosterone undecanoate (Andriol); Placebo · For: Hypogonadism; Androgens
- Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or HypogonadismPivotal-lookingCompleted
Lipocine Inc.Industry
NCT02081300 · 315 participants · Start Feb 2014 · Primary completion May 2015
Drug: Oral testosterone undecanoate, LPCN 1021; Topical testosterone gel 1.62 % · For: Male Hypogonadism
- Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal MenPivotal-lookingCompleted
Marius PharmaceuticalsIndustry
NCT03198728 · 314 participants · Start Jul 5, 2017 · Primary completion May 1, 2020
Drug: SOV2012-F1; AndroGel · For: Hypogonadism, Male
Sites: Birmingham, Alabama; Mobile, Alabama; Tucson, Arizona · 36 sites in all
- Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI TrialPivotal-lookingNot yet recruiting
VA Office of Research and DevelopmentFederal agency
NCT07742553 · 300 participants (planned) · Start Oct 1, 2027 · Primary completion Sep 30, 2031
Drug: testosterone cypionate; finasteride and 2 more · For: Spinal Cord Injury; Spinal Cord Injuries; Injuries, Spinal Cord and 11 more
Sites: Aurora, Colorado; Gainesville, Florida; Tampa, Florida · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use29
- drug abuse13
- asthma10
- atrial fibrillation10
- erectile dysfunction9
- fatigue9
- weight decreased9
- duodenal ulcer8
- erosive duodenitis8
- faeces discoloured8
- headache8
- hypertension8
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2009 | 3 |
| 2010 | 6 |
| 2011 | 2 |
| 2012 | 9 |
| 2013 | 5 |
| 2014 | 4 |
| 2015 | 12 |
| 2016 | 7 |
| 2017 | 5 |
| 2018 | 22 |
| 2019 | 8 |
| 2020 | 9 |
| 2021 | 14 |
| 2022 | 11 |
| 2023 | 19 |
| 2024 | 24 |
| 2025 | 61 |
| 2026 | 34 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism.
Gregorič N, ikonja J, Janež A, et al. · Diabetes Obes Metab 2025 · Randomized Controlled Trial
- Beneficial effects of exercise, testosterone, vitamin D, calcium and protein in older men-A randomized clinical trial.
Midttun M, Overgaard K, Zerahn B, et al. · J Cachexia Sarcopenia Muscle 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Long-term Outcomes of Testosterone Treatment in Men: A T4DM Postrandomization Observational Follow-up Study.
Handelsman DJ, Grossmann M, Yeap BB, et al. · J Clin Endocrinol Metab 2023 · Randomized Controlled Trial
- Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial.
Wittert G, Bracken K, Robledo KP, et al. · Lancet Diabetes Endocrinol 2021 · Clinical Trial, Phase III, Multicenter Study
- Androgens versus placebo or no treatment for idiopathic oligo/asthenospermia.
Vandekerckhove P, Lilford R, Vail A, et al. · Cochrane Database Syst Rev 2000 · Systematic Review
- An empiric treatment for idiopathic oligozoospermia revisited: a 20-year investigative saga.
Koukkou E, Billa E, Kapolla N, et al. · Andrologia 2012 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Marius
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.